Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739165

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739165

Insulin-like Growth Factors

PUBLISHED:
PAGES: 270 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Insulin-like Growth Factors Market to Reach US$355.2 Million by 2030

The global market for Insulin-like Growth Factors estimated at US$281.7 Million in the year 2024, is expected to reach US$355.2 Million by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Mechano Growth Factor, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$222.5 Million by the end of the analysis period. Growth in the Somatomedin C segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$76.7 Million While China is Forecast to Grow at 7.3% CAGR

The Insulin-like Growth Factors market in the U.S. is estimated at US$76.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$72.3 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Insulin-like Growth Factors Market - Key Trends & Drivers Summarized

What Are Insulin-like Growth Factors and Why Are They Gaining Biomedical Attention?

Insulin-like Growth Factors (IGFs), primarily IGF-1 and IGF-2, are naturally occurring polypeptides with structural similarity to insulin and play a critical role in growth, cell proliferation, and tissue regeneration. IGFs act as mediators of growth hormone (GH) activity and are essential in early childhood development, as well as in adult anabolic processes such as muscle repair, bone density maintenance, and organ regeneration. Due to these biological roles, IGFs have become a focal point of research and development across endocrinology, oncology, metabolic diseases, and regenerative medicine.

Beyond their physiological roles, IGFs are being studied for their involvement in pathological conditions, including cancer progression, age-related muscle wasting (sarcopenia), neurodegenerative disorders, and diabetes. The therapeutic potential of recombinant IGF formulations, IGF receptor modulators, and analogs is expanding, especially as personalized medicine and biologics become more mainstream. The dual role of IGFs in promoting tissue regeneration and contributing to abnormal cell proliferation necessitates precise therapeutic targeting, creating opportunities for innovation in drug development, diagnostics, and targeted delivery systems.

How Is Innovation Shaping the Development of IGF-Based Therapies and Diagnostics?

Scientific advancements in molecular biology, protein engineering, and receptor signaling analysis have accelerated the development of IGF-based treatments. Recombinant IGF-1 therapies are currently being explored for conditions such as growth hormone insensitivity (Laron syndrome), severe burns, and muscle atrophy disorders. Biotech firms are actively designing IGF analogs with improved pharmacokinetics and receptor selectivity to maximize therapeutic benefits while minimizing off-target effects. In parallel, IGF-binding proteins (IGFBPs) are being leveraged to regulate bioavailability and enhance the safety profile of IGF-related drugs.

On the diagnostics front, the measurement of circulating IGF-1 levels has gained importance in assessing pituitary function, diagnosing growth disorders, and monitoring treatment efficacy in endocrine therapy. Additionally, IGF receptor expression profiling is emerging as a potential biomarker in oncology, particularly in breast, prostate, and colorectal cancers, where IGF signaling is implicated in tumor growth and resistance to therapy. Advances in bioassay platforms and high-throughput screening technologies are enabling more precise quantification of IGFs and their related pathways, expanding their role in clinical diagnostics and patient stratification.

Which Clinical and Research Domains Are Expanding the Demand for IGF-Based Solutions?

Endocrinology remains the primary domain for IGF utilization, especially in the treatment of pediatric growth disorders and GH deficiencies. However, the scope is broadening rapidly across other therapeutic areas. In musculoskeletal and orthopedic medicine, IGFs are being incorporated into tissue engineering and regenerative therapy protocols to enhance healing and repair of cartilage, tendons, and bone. Sports medicine is another growing application area, where IGF-based therapies are being studied for muscle regeneration and recovery in athletes, albeit amid regulatory and ethical scrutiny.

Oncology represents a significant frontier for IGF research, as several tumors exhibit overexpression of IGF receptors or reliance on IGF signaling for proliferation and survival. This has prompted the development of anti-IGF receptor antibodies and small-molecule inhibitors to disrupt these pathways in targeted cancer therapy. Neurology and geriatrics are emerging domains of interest, where IGFs are being investigated for their neuroprotective effects in Alzheimer's disease, cognitive decline, and age-related neurodegeneration. The broader application of IGFs in cell-based therapies, gene editing, and regenerative medicine underscores their strategic importance in future biomedical innovation.

The Growth in the Insulin-like Growth Factors Market Is Driven by Several Factors…

It is driven by the expanding understanding of IGF signaling in both health and disease, along with the rapid advancement of biopharmaceutical development platforms. The increasing prevalence of endocrine and metabolic disorders, coupled with aging populations worldwide, is fueling demand for therapies that address muscle wasting, growth deficiencies, and degenerative diseases. Technological breakthroughs in protein engineering and recombinant DNA technology are enabling the production of highly specific IGF analogs and modulators, improving therapeutic efficacy and safety.

In parallel, the integration of IGF assays in clinical diagnostics is becoming more common, particularly in growth hormone therapy monitoring, oncology biomarker profiling, and metabolic disease evaluation. The convergence of regenerative medicine and IGF-based interventions-supported by innovations in stem cell research and scaffold design-is opening new therapeutic avenues. Furthermore, expanding clinical research into the role of IGFs in aging, cognition, and immune modulation is positioning these molecules as key targets in next-generation biologic drug pipelines. The combination of cross-disciplinary applications, expanding clinical indications, and robust R&D investments is expected to sustain long-term growth in the insulin-like growth factors market.

SCOPE OF STUDY:

The report analyzes the Insulin-like Growth Factors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Mechano Growth Factor, Somatomedin C, IGF 1); End-Use (Hospitals, Medical Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • ABL Bio
  • Biocon Limited
  • Biomed Industries, Inc.
  • Bio-Techne
  • Braasch Biotech LLC
  • Cell Guidance Systems
  • ConjuChem Biotechnologies Inc.
  • Eli Lilly and Company
  • HyTest Ltd.
  • Kriya Therapeutics
  • Novo Nordisk A/S
  • Oak Hill Bio
  • PerkinElmer (Revvity)
  • Repligen Corporation
  • Rivus Pharmaceuticals
  • Sana Biotechnology
  • STEMCELL Technologies
  • Thermo Fisher Scientific
  • Vertex Pharmaceuticals
  • Zymo Research

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP33978

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Insulin-like Growth Factors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Research Focus on IGFs as Therapeutic Targets in Cancer and Neurological Disorders Drives Market Growth
    • Expansion of Biopharmaceutical R&D Pipelines Spurs Interest in IGF-Based Drug Development
    • Increasing Use of IGF Pathway Modulation in Anti-Aging and Regenerative Medicine Expands Application Scope
    • Surge in Metabolic Disorder Prevalence Strengthens Business Case for IGF-Based Interventions
    • Technological Advances in Protein Engineering Enhance Stability and Efficacy of IGF Therapeutics
    • Collaborative Oncology Trials Highlight the Role of IGF-1 Inhibitors in Targeted Cancer Therapies
    • Rising Investment in Rare Disease Therapeutics Expands Niche Opportunities for IGF Modulators
    • Integration of Biomarkers for IGF Pathway Activation Enhances Precision in Patient Stratification
    • Growing Use of IGF-1 as a Diagnostic and Prognostic Biomarker Fuels Companion Diagnostic Development
    • Increased Focus on Musculoskeletal Recovery and Growth Disorders Drives Demand for IGF-1 Analogs
    • Expansion of Personalized Medicine Approaches Spurs Targeted Use of IGF Therapies in Subpopulations
    • Academic-Industry Collaborations in Endocrinology Research Strengthen Discovery Pipelines for IGF Pathway Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Insulin-like Growth Factors Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Insulin-like Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Insulin-like Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Mechano Growth Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Mechano Growth Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Mechano Growth Factor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Somatomedin C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Somatomedin C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Somatomedin C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for IGF 1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for IGF 1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for IGF 1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Medical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Medical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Medical Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • JAPAN
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • CHINA
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • EUROPE
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Insulin-like Growth Factors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Insulin-like Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • FRANCE
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • GERMANY
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Insulin-like Growth Factors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Insulin-like Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • INDIA
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Insulin-like Growth Factors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Insulin-like Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Insulin-like Growth Factors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Insulin-like Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • AFRICA
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!